Everus Construction Group, Inc. (ECG)
NYSEIndustrialsEngineering & ConstructionSnapshot 2026-09-04
$117.24+1.90%
Close 2026-09-04 · 1-day change
NYSEIndustrialsEngineering & ConstructionSnapshot 2026-09-04
Intact: The reason to own it still holds.
Everus Construction Group grows revenue about 14% yearly. It raised 2026 revenue guidance to $4.35 billion. Operating income improved from $50.98M to $77.68M in one year. Net income rose from $36.67M to $58.32M, showing strong profit growth.
The recent sharp 7.3% one-day stock drop shows market worries. Profit growth may slow if cost control weakens. The sector faces headwinds that could pressure margins and revenue growth.
The price is about 8% above our fair value near $125. Analysts expect 14% revenue growth, which the market broadly prices in. Our fair value is 22% below the Street median, reflecting a more cautious view.
Breaks if: Capex exceeds $110M or falls below $80M in FY26
Breaks if: Net income falls below $45M in any quarter of FY26
Operating income falls below $60M in any quarter of FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with elements of growth. ECG has shown strong revenue growth and improved profitability metrics, but it operates in a high-risk environment with sector challenges.
The market currently reflects a neutral valuation, with ECG priced relatively cheaply compared to its peers. There is an expectations gap, indicating that the market may not fully account for the recent improvements in financial performance.
Management is focused on growing revenue through organic means and acquisitions, which has been successful recently. However, there is a high near-term risk due to potential earnings misses, despite a low probability of such an event.
The future performance of ECG will depend on the execution of its growth strategy and the performance of key sector peers. If major players in the Industrials sector continue to perform well, it could bolster ECG's momentum.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook. The closing of the Epsilon deal also reinforces growth through acquisitions. There are no new threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 10% in FY26
Focus on increasing revenue growth through strategic initiatives and acquisitions.
In the next 1 to 3 years, ECG's trajectory will be influenced by its ability to maintain growth and navigate sector challenges. Not investment advice.